Improving cancer prevention for people with Li-Fraumeni syndrome
Refolding Mutant p53: A Strategy for Cancer Prevention in Li-Fraumeni Syndrome
This study is looking at how to create new medications that can help people with Li-Fraumeni syndrome by fixing a faulty protein linked to cancer, with the goal of preventing tumors from developing.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst of Fox Chase Can Ctr NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10909964 on NIH RePORTER |
What this research studies
This research focuses on individuals with Li-Fraumeni syndrome, a genetic condition that increases the risk of early-onset cancers due to mutations in the TP53 gene. The project aims to develop 'refolder drugs' that stabilize the mutant p53 protein, restoring its ability to function properly and preventing cancer development. By targeting the specific mutations that disrupt p53's DNA binding capabilities, the researchers hope to intervene before tumors form. Patients may benefit from these drugs, which are designed to work regardless of the specific mutation present.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Li-Fraumeni syndrome who carry mutations in the TP53 gene.
Not a fit: Patients without Li-Fraumeni syndrome or those with different genetic mutations unrelated to TP53 may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the risk of cancer in individuals with Li-Fraumeni syndrome.
How similar studies have performed: Previous research has shown promise in targeting p53 mutations, suggesting that this approach could lead to meaningful advancements in cancer prevention.
Where this research is happening
Philadelphia, United States
- Research Inst of Fox Chase Can Ctr — Philadelphia, United States (Active)
Researchers
- Principal investigator: Karanicolas, John — Research Inst of Fox Chase Can Ctr
- Study coordinator: Karanicolas, John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.